{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:50:46Z","timestamp":1790254246239,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["234154"],"award-info":[{"award-number":["234154"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["NCT03204500"],"award-info":[{"award-number":["NCT03204500"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.nrleng.2022.07.003","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T17:10:04Z","timestamp":1661793004000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A phase 2, double-blind, placebo-controlled trial of a valproate\/lithium combination in ALS patients"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-3011","authenticated-orcid":false,"given":"M.-C.","family":"Boll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1323-1679","authenticated-orcid":false,"given":"M.","family":"Alcaraz-Zubeldia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-0119","authenticated-orcid":false,"given":"C.","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gonz\u00e1lez-Esquivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2022.07.003_bib0005","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/archneur.58.3.512","article-title":"How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot","volume":"58","author":"Rowland","year":"2001","journal-title":"Arch Neurol."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0015","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.clinph.2016.04.005","article-title":"Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: a systematic review using individual patient data","volume":"127","author":"Geevasinga","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.nrleng.2022.07.003_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.590573","article-title":"Imaging neurochemistry and brain structure tracks clinical decline and mechanisms of ALS in patients","volume":"11","author":"Andronesi","year":"2020","journal-title":"Front Neurol."},{"issue":"2","key":"10.1016\/j.nrleng.2022.07.003_bib0025","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1017\/cjn.2018.382","article-title":"Is the hypointensity in motor cortex the hallmark of amyotrophic lateral sclerosis?","volume":"46","author":"Boll","year":"2019","journal-title":"Can JNeurol Sci."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0030","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med Res Rev."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0035","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1073\/pnas.0708022105","article-title":"Lithium delays progression of amyotrophic lateral sclerosis","volume":"105","author":"Fornai","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","article-title":"ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment?","volume":"9","author":"Petrov","year":"2017","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.21620","article-title":"Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis","volume":"66","author":"Piepers","year":"2009","journal-title":"Ann Neurol."},{"issue":"1-2","key":"10.1016\/j.nrleng.2022.07.003_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2014.03.005","article-title":"Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis","volume":"340","author":"Boll","year":"2014","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0055","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuroscience.2008.06.040","article-title":"Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"155","author":"Feng","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.nrleng.2022.07.003_bib0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrleng.2022.07.003_bib0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.70.1.70","article-title":"Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5","volume":"70","author":"Jenkinson","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.nrleng.2022.07.003_bib0070","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/WNL.0000000000002251","article-title":"How common are ALS plateaus and reversals?","volume":"86","author":"Bedlack","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0075","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Abe","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.nrleng.2022.07.003_bib0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/14656566.2017.1319937","article-title":"Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis","volume":"18","author":"Sawada","year":"2017","journal-title":"Expert Opin Pharmacother."},{"issue":"5\u20136","key":"10.1016\/j.nrleng.2022.07.003_bib0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/21678421.2015.1026829","article-title":"A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements","volume":"16","author":"Franchignoni","year":"2015","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"key":"10.1016\/j.nrleng.2022.07.003_bib0090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/jnnp-2016-314661","article-title":"What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis","volume":"88","author":"Rooney","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.nrleng.2022.07.003_bib0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00415-016-8313-y","article-title":"Factors predicting survival in ALS: a multicenter Italian study","volume":"264","author":"Calvo","year":"2016","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.nrleng.2022.07.003_bib0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Writing Group; Edaravone (MCI-186) ALS 19 Study Group","year":"2017","journal-title":"Lancet Neurol."},{"issue":"3\u20134","key":"10.1016\/j.nrleng.2022.07.003_bib0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/21678421.2020.1822410","article-title":"A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS","volume":"22","author":"Shefner","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"11","key":"10.1016\/j.nrleng.2022.07.003_bib0110","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol."},{"issue":"9013","key":"10.1016\/j.nrleng.2022.07.003_bib0115","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet."},{"issue":"1-2","key":"10.1016\/j.nrleng.2022.07.003_bib0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","article-title":"Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial","volume":"21","author":"Mora","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"issue":"2","key":"10.1016\/j.nrleng.2022.07.003_bib0125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/nur.20247","article-title":"Considerations in determining sample size for pilot studies","volume":"31","author":"Hertzog","year":"2008","journal-title":"Res Nurs Health."},{"issue":"1","key":"10.1016\/j.nrleng.2022.07.003_bib0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12874-017-0387-4","article-title":"Choice of futility boundaries for group sequential designs with two endpoints","volume":"17","author":"Sch\u00fcler","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"10.1016\/j.nrleng.2022.07.003_bib0135","first-page":"1331","article-title":"Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials","volume":"90","author":"van Eijk","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217358082200089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217358082200089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T12:03:29Z","timestamp":1737806609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S217358082200089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S217358082200089X"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2022.07.003","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2, double-blind, placebo-controlled trial of a valproate\/lithium combination in ALS patients","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2022.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Neurolog\u00eda.","name":"copyright","label":"Copyright"}]}}